<DOC>
	<DOCNO>NCT01184885</DOCNO>
	<brief_summary>This pilot study , assess feasibility , safety toxicity mTOR ( mammalian target Rapamycin ) inhibitor ( MTI ) , rapamycin , administer HyperCVAD ( Hyperfractionated Cyclophosphamide , Vincristine , Doxorubicine Dexamethasone ) , ultimate goal perform phase II study evaluate response rate survival adult Acute Lymphoblastic Leukemia ( ALL ) aggressive lymphoid malignancy .</brief_summary>
	<brief_title>A Pilot Study Determine Safety Tolerability Sirolimus Given With Hyper-CVAD Chemotherapy</brief_title>
	<detailed_description>The primary objective trial characterize feasibility , safety tolerability therapy Hyper-CVAD Rapamycin adult ALL aggressive lymphoid malignancy . This study evaluate effectiveness Rapamycin give combination Hyper-CVAD A treatment cycle , Methotrexate Cytarabine B treatment cycle . Both cycle also contain drug Rituximab patient B cell type leukemia lymphoma . This combination drug study determine whether drug effect treat disease . Current therapeutic regimen induction remission ALL broadly similar . There single best regimen induction therapy . The hyper-CVAD regimen particular interest include asparaginase part therapeutic regimen result induction similar publish regimen . The HyperCVAD regimen without rituximab also accept induction regimen lymphoblastic lymphoma , Burkitt Burkitt like lymphoma , Mantle Cell Lymphoma , ALL elderly . The regimen also use salvage regimen patient diagnosis relapse another induction regimen . This trial add novel agent , mTOR inhibitor ( MTI ) , rapamycin , act synergistically HyperCVAD regimen . This pilot study , assess feasibility , safety toxicity regimen , ultimate goal perform phase II study evaluate response rate survival . This pilot study Hyper-CVAD regimen Rapamycin treatment adult acute lymphoblastic leukemia aggressive lymphoid malignancy . The standard Hyper-CVAD regimen use , addition investigational agent , Rapamycin . Hyper-CVAD alone one current standard induction salvage regimen use treat ALL aggressive lymphoid malignancy . Subjects include either de novo , relapse , refractory ALL another aggressive lymphoid malignancy . Chemotherapy consist 4 ' A ' cycle alternate 4 ' B ' cycle , every 21 day , count recovery allow ( least 14 day apart ) follow : 1A ; 1B ; 2A ; 2B , 3A ; 3B ; 4A ; 4B . This dependent white blood cell count recovery .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients must diagnosis one follow lymphoid malignancy ( new relapse ) : Acute Lymphoblastic Leukemia ( B T cell , Philadelphia Chromosome Negative ) Burkitt Lymphoma Burkitt type Lymphoma Lymphoblastic Lymphoma Mantle Cell Lymphoma Adult T cell Leukemia/ lymphoma 2 . Patients must &gt; 18 year old 3 . Patients must ECOG performance status 0 1 ( see attachment 1 ) . 4 . Patients must life expectancy least 4 week . 5 . Patients must able consume oral medication . 6 . Patients must complete radiotherapy four week prior study entry , 02 week local palliative XRT ( small port ) . 7 . Patients must recover toxic effect prior chemotherapy &lt; grade 2 ( except alopecia ) . 8 . Required initial laboratory value : Creatinine &lt; = 2.0mg/dL ; total direct bilirubin &lt; = 1.5mg/dL ( due leukemia lymphoma ) ; SGPT ( ALT ) &lt; = 3xULN ; glucose &lt; 200 mg/dL , negative pregnancy test woman childbearing potential . 9 . Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing . 10 . Patients may prior stem cell transplant ( autologous allogeneic ) , however may active GvHD , immunosuppression 1 . Patients must receive chemotherapy agent ( except Hydroxyurea ) 2 . Intrathecal ARAC intrathecal methotrexate permissible ( systemic isolated central nervous system ) . 3 . Patients must receive growth factor , except erythropoietin . 4 . Patients current second malignancy require systemic therapy , nonmelanoma skin cancer , eligible . 5 . Patients uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure , myocardial infarction within past 6 month serious uncontrolled cardiac arrhythmia eligible . 6 . Patients take follow drug onstudy eligible : 1 . Carbamazepine ( e.g . Tegretol ) 2 . Rifabutin ( e.g . Mycobutin ) 3 . Rifampin ( e.g . Rifadin ) 4 . Rifapentine ( e.g . Priftin ) 5 . St. John 's Wort may decrease effect sirolimus decrease amount sirolimus body 6 . Clarithromycin ( e.g . Biaxin ) 7 . Cyclosporin e.g . ( Neorla Sandimmune ) 8 . Diltiazem ( e.g . Cardizem ) 9 . Erythromycin ( e.g . AkneMycin , EryTab ) 10 . Itraconazole ( e.g . Sporanox ) 11 . Ketoconazole ( e.g . Nizoral ) 12 . Telithromycin ( e.g . Ketek ) 13 . Verapamil ( e.g . Calan SR , Isoptin , Verelan ) 14 . Voriconazole ( e.g . VFEND ) May increase effect sirolimus increase amount medicine body . [ Can take within 72 hour prior subsequent receiving rapamycin , may take prior time period ] 15 . Tacrolimus ( e.g . Prograf ) May cause liver transplant rejection serious side effect patient sirolimus . 7 . Patients know HIV positivity AIDSrelated illness eligible . 8 . Patients severe concurrent disease judgment investigator would make patient inappropriate entry study ineligible . 9 . Patients must evidence cerebellar dysfunction prior history cerebellar dysfunction AraC administration . 10 . Patients must receive investigational agent within 30 day study entry . 11 . Patients must pregnant breastfeeding . Pregnancy test must obtain female childbearing potential . Pregnant lactate patient ineligible study due unknown human fetal teratogenic toxicity rapamycin . Males female reproductive age may participate unless agree use effective contraceptive method . 12 . Patients uncontrolled infection eligible . Patients must active infection control . Fungal disease must stable least 2 week study entry . Patients bacteremia must document negative blood culture prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hyperCVAD</keyword>
	<keyword>rapamycin</keyword>
	<keyword>lymphoid malignancy</keyword>
	<keyword>lymphoblastic leukemia</keyword>
	<keyword>B T cell</keyword>
	<keyword>philadelphia chromosome negative</keyword>
	<keyword>burkitt lymphoma</keyword>
	<keyword>burkitt-type lymphoma</keyword>
	<keyword>lymphoblastic lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>adult cell leukemia</keyword>
	<keyword>adult cell lymphoma</keyword>
</DOC>